The long awaited Hoffman-La Roche v. Cipla judgement was finally passed last week marking the end of the first phase of a key battle between Big Pharma and the Indian generic industry. Although there are pending suits before the Delhi High Court which have been filed by Roche against several other generics, most prominently NATCO, Glenmark and Dr. Reddy’s, it is expected that the finding of non-infringement against Cipla will pre-determine the fate of those lawsuits as well.
With a premium account you get:
- One year of unrestrcited access to previous interviews, columns and articles
- One year access to all archival material
- Access to all Bar & Bench reports
Already a subscriber ?